Daniel Vitt

Form D signer

Daniel Vitt

Chief Executive Officer at Immunic

Form D signer

Capital raised by Immunic

$200.0M+$200.0M latest round

1 Form D filing · first filed Feb 2026 · New York, NY

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 2 ↗

Career

1 company on file

ImmunicBiotech · New York, NYsince Feb 2026

Chief Executive Officer

Signatory on Immunic's Form D filings · $200.0M raised across 1

Company filings

via EDGAR · Form D for Immunic1

DateCompanyFormAmountRole on filing

Feb 17, 2026ImmunicForm D+$200.0MChief Executive Officer

Form DFeb 17, 2026 · Immunic+$200.0Mas Chief Executive Officer

Overview

Last filing Feb 17, 2026

Daniel Vitt is on file as Chief Executive Officer at Immunic in New York, NY. Immunic has 1 Form D filing on record, $200.0M raised in total. Daniel Vitt appears as a signatory on the company's filings.

Teammates

Immunic · 1

Jason TardioExecutive Officer

Products

Immunic · 1

Vidofludimus calcium (IMU-838)Oral Neurologic Therapy

Vidofludimus calcium is the company's lead oral drug candidate, currently in Phase 3 (ENSURE-1 and ENSURE-2) clinical trials for the treatment of relapsing multiple sclerosis (RMS). It has also demonstrated positive activity in Phase 2 trials for progressive MS and ulcerative colitis. The company plans to initiate a Phase 3 trial for primary progressive multiple sclerosis (PPMS) in 2026.